-

Shareholder Alert: Robbins LLP Announces that Wrap Technologies, Inc. (WRTC) is Being Sued for Misleading Shareholders

SAN DIEGO TEMPE, Ariz.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Wrap Technologies, Inc. (NASDAQ: WRTC) has filed a class action complaint against the company's officers for alleged violations of the Securities Exchange Act of 1934 between April 29, 2020 and September 23, 2020. Wrap Technologies, Inc. is a security technology company whose sole product is the BolaWrap, a remote restraint device.

If you suffered a loss due to Wrap Technologies, Inc.'s misconduct, click here.

Wrap Technologies, Inc. (WRTC) Misstates Viability of its Sole Product

According to the complaint, during the class period, the Company falsely touted the strength of its business and operational prospects. In December 2019, Wrap Technologies announced a 90-day pilot training program with the Los Angeles Police Department (LAPD) using BolaWrap. On July 22, 2020, White Diamond Research published a report alleging that BolaWrap had limited use in field and it was likely that Wrap Technologies did not secure a contract with the LAPD. On September 23, 2020, White Diamond Research published a follow up report titled entitled “Wrap Technologies: Disastrous LAPD BolaWrap Pilot Program Results, No Evidence These Have Been Communicated to Investors." According to the report, the Company failed to disclose key findings from LAPD's trial pilot program and extension because it revealed poor results. On this news, Wrap Technologies' stock dropped 25.43% to close at $6.07 and has yet to recover.

If you purchased Wrap Technologies, Inc. (WRTC) securities between April 29, 2020 and September 23, 2020, you have until November 23, 2020, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com

Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Wrap Technologies, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom